Provider fact sheet · dataset v2026.08.14-4 · last touched 2026-08-14
Eden: GLP-1 programs, prices, and verification status (2026)
Eden is a unverified entry in our universe. Mid-band pricing (~$249–296 reported) with the widest reported state footprint in the compounded lane (~50 states via its platform pharmacies) — which makes Eden the common answer when licensure walls block cheaper programs.
Programs and pricing, in plain sentences
tirzepatide (injection) — status: unverified. Owns Contigo compounding pharmacy (acquired 2025), per third-party reporting
Every figure above carries its status — operator claims come from the provider, reported from third parties we cite, verified only after our own checkout walk. Machine-readable version: providers.json.
Update — August 14, 2026: Verified at its cited source: the April 2026 tirzepatide.us.com comparison lists Eden at $296/mo, the top of our reported $249–296 band. Footprint claim unchanged; license-level verification remains open.
Verification status and open items
Current status: unverified, last touched 2026-08-14. Open verification items: dispensing pharmacy identity, cancellation terms. Source on file: tirzepatide.us.com. Corrections land within 48 hours via the public log — if your checkout contradicts this page, that report changes the dataset.
How Eden fits the market
Mid-band pricing (~$249–296 reported) with the widest reported state footprint in the compounded lane (~50 states via its platform pharmacies) — which makes Eden the common answer when licensure walls block cheaper programs. Verification of the state map is queued; it's the claim that matters most here. Where it lands overall: the price ladder, the category winners, and the program finder all compute from the same dataset this page renders.
Advertising disclosure: outbound provider links may be commission-bearing; our partner relationship with NexLife is disclosed on the ownership page and never alters statuses or rankings.